https://pharminent.com/oncology/oncology-intelligence-digest-may-5-2026/ 2026-05-05T23:15:40Z Pharminent en Oncology Intelligence Digest • May 5, 2026 2026-05-05T23:15:38Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-5-2026/ 2026-05-05T17:25:26Z Pharminent en Strategic News Watch • May 5, 2026 2026-05-05T17:25:24Z Blog https://pharminent.com/quralis-phase-2-data-bolster-case-for-genetic-approach-to-sporadic-als/ 2026-05-05T16:22:50Z Pharminent en QurAlis' Phase 2 data bolster case for genetic approach to sporadic ALS 2026-05-05T13:55:00Z Blog https://pharminent.com/pfizer-stays-the-course-for-2026-guidance-dulling-impact-of-q1-earnings-beat/ 2026-05-05T15:48:08Z Pharminent en Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat 2026-05-05T13:33:05Z Blog https://pharminent.com/cytokinetics-heart-drug-scores-in-closely-watched-trial/ 2026-05-05T15:48:11Z Pharminent en Cytokinetics heart drug scores in closely watched trial 2026-05-05T12:38:00Z Blog https://pharminent.com/specialty-pharmacy-accreditation-dcis-exclusive-analysis-reveals-a-market-at-an-inflection-point/ 2026-05-05T15:48:13Z Pharminent en Specialty Pharmacy Accreditation: DCI's Exclusive Analysis Reveals a Market at an Inflection Point 2026-05-05T10:30:00Z Blog https://pharminent.com/lannett-lanexa-biologics-and-sunshine-lake-secure-fda-approval-for-langlara/ 2026-05-05T15:48:16Z Pharminent en Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara 2026-05-05T10:08:28Z Blog https://pharminent.com/seismic-shift-as-obesity-overtakes-cancer-for-rd-returns/ 2026-05-05T15:48:16Z Pharminent en 'Seismic shift' as obesity overtakes cancer for R&D returns 2026-05-05T09:58:57Z Blog https://pharminent.com/latus-bio-secures-97m-in-funding-to-boost-gene-therapy-access/ 2026-05-05T15:48:17Z Pharminent en Latus Bio secures $97m in funding to boost gene therapy access 2026-05-05T09:53:25Z Blog https://pharminent.com/autoimmune-disease-biotech-odyssey-sets-terms-for-225m-ipo/ 2026-05-05T15:48:18Z Pharminent en Autoimmune disease biotech Odyssey sets terms for $225m IPO 2026-05-05T08:52:32Z Blog https://pharminent.com/cytospire-hauls-in-83m-for-a-new-type-of-t-cell-engager/ 2026-05-05T15:41:43Z Pharminent en Cytospire hauls in $83M for a new type of T cell engager 2026-05-05T07:00:00Z Blog https://pharminent.com/amneal-agrees-to-acquire-kashiv-biosciences-for-total-payment-up-to-1-1-billion/ 2026-05-05T15:41:44Z Pharminent en Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 Billion 2026-05-04T22:54:28Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-4-2026/ 2026-05-04T22:18:09Z Pharminent en Rare Disease & Gene Therapy Digest • May 4, 2026 2026-05-04T22:18:06Z Blog https://pharminent.com/ucb-enters-2-2-billion-deal-to-acquire-candid-therapeutics/ 2026-05-04T22:13:25Z Pharminent en UCB Enters $2.2 Billion Deal to Acquire Candid Therapeutics 2026-05-04T22:10:38Z Blog https://pharminent.com/part-d-mail-order-prescription-drugs/ 2026-05-05T15:41:45Z Pharminent en Part D Mail Order Prescription Drugs 2026-05-04T17:56:16Z Blog https://pharminent.com/part-d-retail-prescription-drugs/ 2026-05-05T15:41:46Z Pharminent en Part D Retail Prescription Drugs 2026-05-04T17:44:09Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-4-2026/ 2026-05-04T17:37:23Z Pharminent en Strategic News Watch • May 4, 2026 2026-05-04T17:37:20Z Blog https://pharminent.com/odyssey-eyes-236m-for-renewed-nasdaq-bid-seaport-docks-on-nasdaq/ 2026-05-04T17:15:50Z Pharminent en Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq 2026-05-04T17:15:50Z Blog https://pharminent.com/celcuity-strengthens-case-for-asco-spotlighted-breast-cancer-drug/ 2026-05-05T15:41:47Z Pharminent en Celcuity strengthens case for ASCO-spotlighted breast cancer drug 2026-05-04T16:23:00Z Blog https://pharminent.com/223-an-interview-with-dr-antn-blatnik-on-the-molecular-mechanisms-driving-neuromuscular-disease/ 2026-05-04T17:15:52Z Pharminent en 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease 2026-05-04T14:57:02Z Blog https://pharminent.com/eli-lilly-to-acquire-kelonia-therapeutics/ 2026-05-04T17:15:54Z Pharminent en Eli Lilly to Acquire Kelonia Therapeutics 2026-05-04T14:30:19Z Blog https://pharminent.com/gene-therapys-evidence-problem-lessons-from-recent-fda-decisions/ 2026-05-04T17:15:55Z Pharminent en Gene therapy's evidence problem--lessons from recent FDA decisions 2026-05-04T13:23:03Z Blog https://pharminent.com/pci-adds-us-sterile-fill-finish-capabilities-through-1b-global-expansion-drive/ 2026-05-04T17:15:56Z Pharminent en PCI adds US sterile fill/finish capabilities through $1B global expansion drive 2026-05-04T12:57:47Z Blog https://pharminent.com/first-fda-odac-meeting-without-pazdur-highlights-conceptual-challenges-with-trial/ 2026-05-04T17:15:57Z Pharminent en First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial 2026-05-04T12:07:00Z Blog https://pharminent.com/summit-shares-descend-as-pd-1-vegf-asset-misses-early-survival-mark/ 2026-05-04T17:15:57Z Pharminent en Summit shares descend as PD-1/VEGF asset misses early survival mark 2026-05-04T11:29:05Z Blog https://pharminent.com/ucb-to-acquire-candid-in-2-2b-bet-on-bispecifics-for-autoimmune-diseases/ 2026-05-04T17:15:58Z Pharminent en UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases 2026-05-04T10:20:00Z Blog https://pharminent.com/novo-nordisk-to-launch-ozempic-for-type-2-diabetes-in-us-2/ 2026-05-04T17:15:58Z Pharminent en Novo Nordisk to launch Ozempic for type 2 diabetes in US 2026-05-04T08:16:55Z Blog https://pharminent.com/pfizer-arvinas-join-serd-club-with-veppanu-approval/ 2026-05-04T17:15:59Z Pharminent en Pfizer, Arvinas join SERD club with Veppanu approval 2026-05-04T07:33:34Z Blog